Short-term responders of non-small cell lung cancer patients to EGFR tyrosine kinase inhibitors display high prevalence of TP53 mutations and primary resistance mechanisms

被引：0
|
作者：
Fan, Y. [1 ]
Xu, Y. [1 ]
Tong, X. [2 ]
Yan, J. [3 ]
Wu, X. [2 ]
Shao, Y. W. [2 ]
机构：
[1] Zhejiang Canc Hosp, Key Lab Diag & Treatment Technol Thorac Canc, Hangzhou, Zhejiang, Peoples R China
[2] Geneseeq Technol Inc, Translat Med Res Inst, Toronto, ON, Canada
[3] Nanjing Geneseeq Technol Inc, Med Dept, Nanjing, Jiangsu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
157P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
    Wang, Jun
    Wang, Baocheng
    Chu, Huili
    Yao, Yunfeng
    ONCOTARGETS AND THERAPY, 2016, 9 : 3711 - 3726
  • [32] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Xiuning Le
    Eric Nadler
    Daniel B. Costa
    John Victor Heymach
    Targeted Oncology, 2023, 18 : 807 - 817
  • [33] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    LUNG CANCER, 2021, 156 : S40 - S40
  • [34] EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast
    Le, Xiuning
    Nadler, Eric
    Costa, Daniel B.
    Heymach, John Victor
    TARGETED ONCOLOGY, 2023, 18 (06) : 807 - 817
  • [35] Impact of EGFR-Tyrosine Kinase Inhibitors for Postoperative Recurrent Non-Small Cell Lung Cancer Harboring EGFR Mutations
    Igawa, S.
    Sato, Y.
    Kusuhara, S.
    Harada, S.
    Shirasawa, M.
    Kurahayashi, S.
    Okuma, Y.
    Sugimoto, A.
    Sugita, K.
    Nakahara, Y.
    Otani, S.
    Fukui, T.
    Yokoba, M.
    Mitsufuji, H.
    Kubota, M.
    Katagiri, M.
    Sasaki, J.
    Masuda, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2126 - S2127
  • [36] Exploring the utility of TP53 mutations as prognostic markers in patients with non-small cell lung cancer (NSCLC)
    Wang, Y.
    Zuo, J.
    Feng, L.
    Fan, Z.
    Wang, L.
    Zhang, X.
    Han, J.
    Zhou, X.
    Ye, J.
    Li, B.
    Lizaso, A.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S799 - S800
  • [37] Efficacy of EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients Harboring Different Types of EGFR Mutations:A Retrospective Analysis
    刘华丽
    韩光
    彭敏
    翁一鸣
    袁静萍
    杨桂芳
    于金明
    宋启斌
    Current Medical Science, 2017, 37 (06) : 864 - 872
  • [38] Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
    Hua-li Liu
    Guang Han
    Min Peng
    Yi-ming Weng
    Jing-ping Yuan
    Gui-fang Yang
    Jin-ming Yu
    Qi-bin Song
    Current Medical Science, 2017, 37 : 864 - 872
  • [39] Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis
    Liu, Hua-li
    Han, Guang
    Peng, Min
    Weng, Yi-ming
    Yuan, Jing-ping
    Yang, Gui-fang
    Yu, Jin-ming
    Song, Qi-bin
    JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2017, 37 (06) : 864 - 872
  • [40] Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study
    Kanazu, Masaki
    Mori, Masahide
    Kimura, Madoka
    Nishino, Kazumi
    Shiroyama, Takayuki
    Nagatomo, Izumi
    Ihara, Shoichi
    Komuta, Kiyoshi
    Suzuki, Hidekazu
    Hirashima, Tomonori
    Kumagai, Toru
    Imamura, Fumio
    THORACIC CANCER, 2021, 12 (01) : 90 - 96
12345